Promacta may cause hepatotoxicity. Promacta, in combination with Interferon and Ribavirin in patients with chronic hepatitis C, may increase the risk of hepatic decompensation. Patients receiving therapy with Promacta must have regular monitoring of serum liver tests. Discontinue Promacta if ALT levels increase to greater than or equal to 3X upper limit of normal ( ULN ) in patients with normal liver function or 3X baseline in patients with pre-treatment elevations in transaminases and are: progressive; or persistent for greater than or equal to 4 weeks; or accompanied by increased direct bilirubin; or accompanied by clinical symptoms of liver injury or evidence of hepatic decompensation. Reinitiating treatment with Promacta is not recommended and should be considered only with close medical supervision and under exceptional circumstances where the potential benefit outweighs the risk.

Additional safety information regarding risk of hepatotoxicity: - Reinitiating treatment with Promacta is not recommended. If the potential benefit for reinitiating treatment with Promacta is considered to outweigh the risk for hepatotoxicity, then cautiously reintroduce Promacta and measure serum liver tests weekly during the dose adjustment phase. If liver test abnormalities persist, worsen or recur, then permanently discontinue Promacta.

Hepatic Decompensation: - Chronic hepatitis C patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alfa Interferons. Monitor patients with low albumin levels or with MELD score greater than or equal to 10 at baseline.

Thrombotic / Thromboembolic Complications: - Thrombotic / thromboembolic complications may result from increases in platelet counts with Promacta. Reported thrombotic / thromboembolic complications included both venous and arterial events and were observed at low and at normal platelet counts. Consider the potential for an increased risk of thromboembolism when administering Promacta to patients with known risk factors for thromboembolism. To minimize the risk for thrombotic / thromboembolic complications, do not use Promacta in an attempt to normalize platelet counts. Follow the dose adjustment guidelines to achieve and maintain target platelet counts.
In 2 controlled clinical trials in patients with chronic hepatitis C and thrombocytopenia, 3% ( 31/955 ) treated with Promacta experienced a thrombotic event compared to 1% ( 5/484 ) on placebo. The majority of events were of the portal venous system ( 1% in patients treated with Promacta versus less than 1% for placebo ).
In a controlled trial in non-ITP thrombocytopenic patients with chronic liver disease undergoing elective invasive procedures ( n=292 ), seven thrombotic complications ( 6 patients ) were reported within the group that received Promacta and three thrombotic complications ( 2 patients ) within the placebo group. All of the thrombotic complications reported in the group that received Promacta were portal vein thrombosis, with thrombotic complications occurring in five of the six patients at a platelet count above 200 x 109/L. Promacta is not indicated for the treatment of thrombocytopenia in patients with CLD in preparation for invasive procedures.

Drug Interactions - Promacta must not be taken within 4 hours of any medications or products containing polyvalent cations such as antacids, dairy products, and mineral supplements.

Adverse Reactions - The most common adverse reactions in 2 randomized placebo-controlled clinical trials in thrombocytopenic patients with chronic hepatitis C ( greater than or equal to 10% and greater than placebo ) for Promacta versus placebo were: anemia ( 40% vs 35% ), pyrexia ( 30% vs 24% ), fatigue ( 28% vs 23% ), headache ( 21% vs 20% ), nausea ( 19% vs 14% ), diarrhea ( 19% vs 11% ), decreased appetite ( 18% vs 14% ), influenza-like illness ( 18% vs 16% ), asthenia ( 16% vs 13% ), insomnia ( 16 % vs 15% ), cough ( 15% vs 12% ), pruritus ( 15% vs 13% ), chills ( 14% vs 9% ), myalgia ( 12% vs 10% ), alopecia ( 10% vs 6% ), and peripheral edema ( 10% vs 5% ).

Source: GSK, 2012

XagenaMedicine2012